SARS-CoV-2 has rapidly spread across the globe and infected hundreds of millions of
people worldwide. As our experience with this virus continues to grow, our understanding of …

The novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused
a pandemic of coronavirus disease 2019 (COVID-19). Across the globe, a subset of patients …

Background Coronavirus disease 2019 (COVID-19) can result in a large variety of chronic
health issues such as impaired lung function, reduced exercise performance and diminished …

At the end of 2019, a highly contagious infection began its ominous conquest of the world. It
was soon discovered that the disease was caused by a novel coronavirus designated as …

Background The long-term pulmonary sequelae of COVID-19 is not well known. Purpose To
characterize patterns and rates of improvement of chest CT abnormalities 1 year after …

While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and
scientific communites since it was first reported in late 2019, we are only beginning to …

Post COVID-19 sequelae are a constellation of symptoms often reported after recovering
from COVID-19. There is a need to better understand the clinical spectrum and long-term …

Acute respiratory distress syndrome (ARDS) followed by repair with lung remodeling is
observed in COVID-19. These findings can lead to pulmonary terminal fibrosis, a form of …

The pathogenesis of lung fibrosis involves hyperactivation of innate and adaptive immune
pathways that release inflammatory cytokines and growth factors such as tumor growth …

Pirfenidone (PFN) is an anti-fibrotic drug with significant anti-inflammatory property used for
treatment of fibrotic conditions such as idiopathic pulmonary fibrosis (IPF). In the coronavirus …